17‐β‐estradiol reduces surface PD‐L1 expression in estrogen receptor‐positive breast cancer but not type 1 endometrial cancer cells
Clinical and Translational Medicine · 2023
DOI: 10.1002/ctm2.1330 ↗Kurz gefasst
Leserbrief in der Zeitschrift Clinical and Translational Medicine, 2023. Verfasst von Hongzhuo Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Breast Neoplasms, Endometrial Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Queensland, National Health and Medical Research Council.
Abstract (Originalsprache)
17-β-estradiol reduces surface PD-L1 expression in estrogen receptor-positive breast cancer but not type 1 endometrial cancer cellsDear Editor, We report here that 17-β-estradiol (E2), through ERα (estrogen receptor α), inhibits IFN-γ-induced surface PD-L1 (programmed death-ligand 1, CD274) level in advanced ER + /HER2 -breast cancer (BC) but not in triple negative BC (TNBC) or endometrial cancer (EC).This study implies that mTOR and MAPK pathways can reduce the surface PD-L1 level and diminish immune evasion via ERα.It also has important implications on endocrine resistance and the limitations of mTOR or MAPK-targeted therapies for treating advanced ER + /HER2 -BC.Tumour cell surface PD-L1 binds to the PD-1 (programmed death 1, CD279) receptor on the surface of activated tumour-infiltrating lymphocytes (TILs), leading to tumour immune evasion.However, high-level surface PD-L1 is observed in ER -BC and EC tissues and the TILs 1,2 but rarely in ER + BC tumors. 2 Additionally, it remains unclear why ER + patients are less responsive than those with ER -cancers to anti-PD-1/PD-L1 therapy.E2 functions primarily through the two receptors of ERα and ERβ in both cancers.Approximately 60%-65% of BC cases are ER + /HER2 -luminal A subtype, 3 and 80% of EC are of type 1 ER + cancers.4 E2 reduces the IRF-1 protein and mRNA levels in murine splenocytes 5 and MCF-7 cell line, 6 respectively, implying that E2 may reduce the surface PD-L1 in both diseases.However, how E2 regulates tumour cell surface PD-L1 expression in ER + BC and type1 EC is elusive.By qRT-PCR, BC cell lines MCF-7 (ERα + /PD-L1 trace ) and MDA-MB-231 (ERα -/PD-L1 high ), and EC cell lines Ishikawa (ERα + /PD-L1 trace , type 1) and TEN (ERα -/PD-L1 trace , type 2) were selected; flow cytometry was employed for this study.We examined the PD-L1 transcripts in a cohort of 25 EC specimens and detected a significantly higher PD-L1 transcriptional level in the type 2 EC group than in non-EC, but not for type 1 EC (Tables S1-S4 and Figures S1 and S2).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia.
- Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, Australia.
- School of Biomedical Sciences at the Translational Research Institute, Queensland University of Technology, Brisbane, Queensland, Australia.
ORCID-Profile: Chen Chen
Förderung
- University of Queensland
- National Health and Medical Research Council
Zitieren
APA
Li, H., Gu, W., Jeffery, P., & Chen, C. (2023). 17‐β‐estradiol reduces surface PD‐L1 expression in estrogen receptor‐positive breast cancer but not type 1 endometrial cancer cells. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.1330
Vancouver
Li H, Gu W, Jeffery P, Chen C. 17‐β‐estradiol reduces surface PD‐L1 expression in estrogen receptor‐positive breast cancer but not type 1 endometrial cancer cells. Clinical and Translational Medicine. 2023. doi:10.1002/ctm2.1330
BibTeX
@article{Li2023,
author = {Li, Hongzhuo and Gu, Wenyi and Jeffery, Penny and Chen, Chen},
title = {17‐β‐estradiol reduces surface PD‐L1 expression in estrogen receptor‐positive breast cancer but not type 1 endometrial cancer cells},
journal = {Clinical and Translational Medicine},
year = {2023},
doi = {10.1002/ctm2.1330}
}
EUVIMED